Issue link: http://osercommunicationsgroup.uberflip.com/i/1104451
Chain Drugstore Daily 3 7 Sunday, April 28, 2019 with nationwide television and print advertising, have made the HurryCane a household name. The majority of all HurryCane pur- chases are from retail shelves. HurryCane customers are coming into stores to make their purchase. Their targeted destination shopping com- bined with higher-than-average spend- ing power makes for a valuable con- sumer coming through store doors. More than 25 percent of HurryCane purchases are made by repeat cus- tomers buying additional colors and accessories. Making sure additional colors are available is a great way to increase sales. HurryRoll ® is the newest addition to the HurryCane family of products. This quality rollator combines all the Medical Supply Sales (Cont'd. from p. 1) features that consumers have said are important to them. An upgraded padded backrest and seat, patented braking system and a carry bag and cup holder are included in one stylish package. Available in two colors, the HurryRoll is a great choice for con- sumers looking for their next high- quality mobility product. And like the HurryCane, the HurryRoll is supported by a nationwide print and television media campaign. Millions of customers love their HurryCane and trust the HurryCane brand. Stop by the Drive DeVilbiss Healthcare booth #540 to see the HurryCane and HurryRoll. For more information, go to www.drive medical.com, call 877.224.0946 ext. 4335, email hurryretail@drivemedical.com or stop by booth #540. both regular and extended release solid dosage formulations. Similarly, we are opening up a new packaging block with six new bulk tablet and capsule packag- ing lines as well as two blister packaging lines. Additionally, Aurobindo has started working on plans for the expansion of manufacturing of specialty formulations within its Durham, North Carolina manu- facturing facility. Our Indian-based manufacturing sites are also expanding to account for growth in the marketplace. One of the most exciting additions is a new state-of- the-art manufacturing plant dedicated to the U.S. market. Designed with the latest technology, all quality aspects are inte- grated into the manufacturing process. The continuous flow of material from dispensing to final packaging has dra- matically reduced the potential for con- tamination, increasing batch yields and reduced overall cycle times. Although Aurobindo's integrated supply chain is extensive, it's also nimble enough to quickly shift with market change. Our front-to-back fully integrat- ed AuroControl strategy makes us excep- tionally agile in our ability to respond to changes in the market. This allows us to reprioritize and adjust for the ever- increasing scale and more complex needs of our customers. AuroControl enables us to be uniquely positioned to continually grow, expand operations and deliver unsurpassed stability, quality and value to our customers. CDD: What is Aurobindo doing to miti- Aurobindo (Cont'd. from p. 1) gate risk in supplying critical pharmaceu- ticals to the market? DP: Aurobindo's AuroControl corporate strategy ensures complete oversight and control across all critical functions in pharmaceutical development, manufac- turing and distribution. Located both domestically and overseas, Aurobindo operates via an unsurpassed industrial scale and manufacturing infrastructure. It includes multiple finished dose and API facilities, with products qualified across multiple sites to increase flexibility while reducing risk and time to market. Likewise, Aurobindo is heavily invested in the distribution link of our global supply chain. We recently opened the doors to a brand new warehouse and distribution center. This new facility is comprised of 567,000 square feet of warehousing and multiuse space, and uti- lizes Automated Storage and Retrieval System (ASRS) warehousing framework and technology. The ASRS is an ultra- high-density storage system, enabling system-driven inventory management from receipt of finished goods to ship- ment. It allows for capacity of up to 40,000 pallets, enabling an increase in service levels, strategic inventory builds and faster, more efficient order fulfillment for our customers. Ultimately, this level of control reduces dependence on exter- nal factors and delivers an exceptionally high level of quality, value, consistency and breadth of line for our customers. Visit Aurobindo at booth #444. For more information, contact your account man- ager, visit www.aurobindousa.com or call 866.850.2876. representing over $14 billion in brand sales. CDD: Do you only sell authorized gener- ics when other generic competition is present? CA: Not necessarily. There are multiple scenarios where Prasco Authorized Generics are available, but other generics have little to no presence. As an example, we have launched first-to-market generics through a preemptive authorized generic. This was the case in our recent launch of an albuterol inhaler. In fact, we have launched more preemptive AGs than any- one. Another circumstance is when other generics exit the market, or have limited ability to supply. Even when other generic competition is not present, there are often ways for authorized generics to provide more access and affordability. Prasco (Cont'd. from p. 1) CDD: Where do you see authorized generics in the future? CA: I believe authorized generics will continue a strong growth trajectory. In light of the continuing discussions about the need to improve access and afford- ability, there will be more opportunities for AGs. Launching an authorized gener- ic will continue to be a smart solution for brand companies, with positive results for patients and payers. In the coming years, I see expansion of AGs through increased patient awareness and choice, and I look forward to seeing how our business model evolves in the biosimilar space. The future always starts with inno- vation, and when Prasco's partners are the world's most innovative in pharma- ceutical research and development, our future looks brighter than ever. For more information, go to www .prasco.com or stop by booth #224. Employers are also reacting to the increasing cost of healthcare, with more of them opting to offer high-deductible health plans for their employees (Henry J Kaiser Family Foundation, 2018 Employer Health Benefits Survey, www.slideshare.net/KaiserFamilyFound ation/2018-employer-health-benefits- survey, accessed January 2019). As one of the key priorities in health- care is to better manage and contain cost, this is leading to formulary restrictions, higher co-pays and deductibles and increas- es in premiums. With the increased out-of- pocket spend, people with diabetes are looking for more affordable options. This is leading to a growing over-the-counter mar- ket for blood glucose monitoring supplies, which is the fastest growing segment (www.pwc.com/us/en/hr-management/ publications/pdf/pwc-touchstone-2017.pdf, w w w. n i e l s e n . c o m / u s / e n / i n s i g h t s / news/2017/capitalizing-on-consumers- i n c r e a s e d - f o c u s - o n - h e a l t h - a n d - wellness.html). Being able to effectively measure glucose levels is critical in the self-man- agement of diabetes both for Type 1 and Type 2 patients. It allows people to track their diabetes, calculate the appropriate doses of certain medications and see how food or lifestyle affect their blood glu- Ascensia (Cont'd. from p. 1) cose level. Therefore, it is important for patients to have access to highly effective and accurate diabetes supplies in order to facilitate long-term management of dia- betes. Patients are already buying test strips over the counter due to cost and convenience. It might be cheaper than co-pay and they can pick their product off the shelf. Ascensia has made CON- TOUR ® NEXT test strips available as 35 and 70 count boxes over-the-counter as an affordable cash option. The patients can now access a best-in-class product at an affordable price. They are the ideal option for people who need to self-pay because they are underinsured or uninsured, or for people presenting with an unbranded prescription. Being available over-the-counter also pro- vides people with diabetes with the freedom to choose the brand they pre- fer. These factors have made the CON- TOUR NEXT test strips the No. 1 brand- ed over-the-counter test strip (Reference: OTC brand volume, IRI Cash Data CYTD July 2018), providing people with diabetes with a product with a remark- able accuracy at an affordable price, to help them better manage their diabetes. For more information, go to www .ascensia.com or stop by booth #6. As the first and only over-the- counter eye drop developed with low- dose brimonidine tartrate 0.025% for the treatment of ocular redness, LUMIFY works differently by selectively targeting redness. Compared to other redness relievers, it alleviates the potential decrease of blood and oxygen through the eye, which helps reduce the risk of common side effects, like rebound red- ness or loss of efficacy over time, when used as directed. In addition, many new over-the- counter medicines go through the tra- ditional "prescription-first" route. LUMIFY, on the other hand, was directly approved as an over-the- counter product, an infrequent occur- rence in the world of OTC approvals. Today, consumers can find the product at a premium location on shelf at many retailers. "With LUMIFY, we knew we had a unique opportunity to bring growth to a once flat personal care category," said Chris Marschall, Vice President, Marketing, Bausch + Lomb Consumer Healthcare. "By collaborating with retailers, we've been able to create cap- tivating in-store displays and signage throughout the store, helping to drive cross-category partnership. These Bausch + Lomb (Cont'd. from p. 1) efforts, coupled with a substantial national marketing campaign including TV, PR and social media, are bringing first-time users to the category." Not only has the product been a hit in-store, it's had much success at home, and in the media. The product has a 45 percent repeat purchase rate for house- hold trials, which has been encouraged by its positive coverage in consumer-fac- ing magazines. Testimonials in women's lifestyle, beauty and fashion publications and on social media have praised the product, encouraging readers to stock up on the eye drops that can help red and irritated eyes appear brighter and more radiant – for photo opportunities, travel, and for those days when your eyes need a little help. LUMIFY has also been hon- ored with awards from New You, the Zoe Report, New Beauty, and BRIDES mag- azines. "We continue to be pleased with the positive feedback we receive for this product and remain committed to bring- ing new and unique products like LUMI- FY to market to meet the evolving eye health needs of our customers." For more information on LUMIFY, visit www.lumifydrops.com. Attendees of the NACDS Annual Meeting can also visit the Bausch + Lomb booth, bungalow #12 to learn more.